Does Sangamo Therapeutics Inc (NASDAQ:SGMO) Have Gas After Even Less Sellers Involved?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Logo

Investors sentiment increased to 1.44 in 2018 Q2. Its up 0.20, from 1.24 in 2018Q1. It increased, as 33 investors sold Sangamo Therapeutics, Inc. shares while 39 reduced holdings. 35 funds opened positions while 69 raised stakes. 59.91 million shares or 12.27% more from 53.36 million shares in 2018Q1 were reported.
Ameritas Inv Prtn Inc stated it has 0.01% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Voya Investment Management Ltd Liability has invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). West Oak Capital Lc owns 50 shares. Public Employees Retirement Sys Of Ohio holds 120,970 shares or 0.01% of its portfolio. California Employees Retirement invested in 112,130 shares or 0% of the stock. Asset has invested 0.01% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Tci Wealth Advsrs holds 0.01% or 1,900 shares in its portfolio. Hightower Ltd Llc has 24,055 shares. Jpmorgan Chase And stated it has 97,894 shares or 0% of all its holdings. New York-based Metropolitan Life Insurance Commerce Ny has invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). 1,000 are owned by Hanson Mcclain. Geode Capital Mngmt Ltd Limited Liability Company has 0% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Davenport & Company Limited Company has invested 0.01% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). State Of Wisconsin Invest Board holds 0% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 103,300 shares. Baker Bros Advsrs Ltd Partnership owns 1.28M shares.

Since June 6, 2018, it had 3 insider purchases, and 12 insider sales for $718,627 activity. $83,350 worth of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) was sold by Conner Edward R. on Wednesday, June 6. Shares for $78,365 were sold by Yi Kathy on Friday, June 15. JEFFS ROGER had bought 7,408 shares worth $100,487.

The stock of Sangamo Therapeutics Inc (NASDAQ:SGMO) registered a decrease of 0.59% in short interest. SGMO’s total short interest was 11.92M shares in December as published by FINRA. Its down 0.59% from 12.00 million shares, reported previously. With 2.10 million shares average volume, it will take short sellers 6 days to cover their SGMO’s short positions.

The stock increased 3.78% or $0.45 during the last trading session, reaching $12.37. About 1.27 million shares traded. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 10.73% since December 2, 2017 and is uptrending. It has underperformed by 4.89% the S&P500.

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company has market cap of $1.26 billion. The companyÂ’s proprietary zinc finger DNA-binding protein technology enables specific genome editing and gene regulation. It currently has negative earnings. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Ratings Coverage

Among 3 analysts covering Sangamo Therapeutics (NASDAQ:SGMO), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Sangamo Therapeutics has $24 highest and $11 lowest target. $17.50’s average target is 41.47% above currents $12.37 stock price. Sangamo Therapeutics had 3 analyst reports since June 20, 2018 according to SRatingsIntel. The firm has “Neutral” rating by Guggenheim given on Friday, November 9. The rating was downgraded by JP Morgan on Wednesday, November 14 to “Neutral”.

More notable recent Sangamo Therapeutics, Inc. (NASDAQ:SGMO) news were published by: Streetinsider.com which released: “Baker Bros. Advisors 13F for Quarter Ended Sept. 30, 2018 – StreetInsider.com” on November 14, 2018, also Fool.com with their article: “Better Buy: CRISPR Therapeutics AG vs. Sangamo Therapeutics Inc. – Motley Fool” published on November 18, 2018, Seekingalpha.com published: “Sangamo: The Secondary Was Ill-Timed Or Not – Seeking Alpha” on May 08, 2018. More interesting news about Sangamo Therapeutics, Inc. (NASDAQ:SGMO) were released by: Nasdaq.com and their article: “Gilead’s Vemlidy Gets Approval in China for HBV Infection – Nasdaq” published on November 20, 2018 as well as Nasdaq.com‘s news article titled: “Implied Volatility Surging for Sangamo Therapeutics (SGMO) Stock Options – Nasdaq” with publication date: September 25, 2018.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.